RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+40.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.16B
AUM Growth
+$3.16B
(+26%)
Cap. Flow
+$71.7M
Cap. Flow
% of AUM
2.27%
Top 10 Holdings %
Top 10 Hldgs %
29.57%
Holding
150
New
12
Increased
35
Reduced
32
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$73.2M |
| 2 |
Humana
HUM
|
$67.8M |
| 3 |
Aprea Therapeutics
APRE
|
$33.2M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$24.9M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$20.7M |
Top Sells
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$49M |
| 2 |
MDCO
Medicines Co
MDCO
|
$41.8M |
| 3 |
AbbVie
ABBV
|
$39.8M |
| 4 |
Stryker
SYK
|
$38.7M |
| 5 |
Cigna
CI
|
$29M |
Sector Composition
| 1 | Healthcare | 90.33% |
| 2 | Consumer Staples | 0.66% |
| 3 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zai Lab
ZLAB
$3.77B
| $26M | 0.82% |
625,000
+50,000
| +9% | +$2.08M |
|
|
BOLD
52
DELISTED
Audentes Therapeutics, Inc
BOLD
| $24.5M | 0.78% |
410,000
| – | – |
|
53
West Pharmaceutical
WST
$17.5B
| $22.9M | 0.72% |
152,500
| – | – |
|
54
Madrigal Pharmaceuticals
MDGL
$9.76B
| $22.8M | 0.72% |
250,200
-22,200
| -8% | -$2.02M |
|
|
ALLK
55
DELISTED
Allakos
ALLK
| $22.4M | 0.71% |
235,000
-55,000
| -19% | -$5.24M |
|
|
ACHN
56
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $22.2M | 0.7% |
3,685,000
-140,000
| -4% | -$844K |
|
57
Incyte
INCY
$17B
| $21.8M | 0.69% |
250,000
-62,300
| -20% | -$5.44M |
|
|
PTLA
58
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $21.5M | 0.68% |
900,000
-150,000
| -14% | -$3.58M |
|
|
IMMU
59
DELISTED
Immunomedics Inc
IMMU
| $21.2M | 0.67% |
1,000,000
+105,000
| +12% | +$2.22M |
|
|
GBT
60
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21.1M | 0.67% |
265,000
| – | – |
|
61
Freshpet
FRPT
$2.65B
| $21M | 0.66% |
355,250
| – | – |
|
|
RDUS
62
DELISTED
Radius Health, Inc.
RDUS
| $20.2M | 0.64% |
1,000,200
-299,800
| -23% | -$6.04M |
|
|
XENT
63
DELISTED
Intersect ENT, Inc
XENT
| $19.9M | 0.63% |
800,000
-72,500
| -8% | -$1.81M |
|
|
NVTA
64
DELISTED
Invitae Corporation
NVTA
| $19.4M | 0.61% |
1,200,000
+75,000
| +7% | +$1.21M |
|
65
Insmed
INSM
$30.9B
| $19.1M | 0.6% |
800,000
-90,000
| -10% | -$2.15M |
|
|
FTSV
66
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $17.7M | 0.56% |
+450,000
| New | +$17.7M |
|
67
Theravance Biopharma
TBPH
$706M
| $17M | 0.54% |
655,200
+105,200
| +19% | +$2.72M |
|
68
Adaptive Biotechnologies
ADPT
$2B
| $16.3M | 0.52% |
545,000
| – | – |
|
|
69
Cigna
CI
$79.7B
| $15.3M | 0.48% |
75,000
-141,900
| -65% | -$29M |
|
70
HealthEquity
HQY
$8.15B
| $15.2M | 0.48% |
+205,000
| New | +$15.2M |
|
71
OneSpaWorld
OSW
$2.31B
| $15.2M | 0.48% |
+900,000
| New | +$15.2M |
|
72
Phreesia
PHR
$1.87B
| $15.1M | 0.48% |
565,000
+204,000
| +57% | +$5.43M |
|
73
Guardant Health
GH
$8.28B
| $14.8M | 0.47% |
190,000
| – | – |
|
74
NovoCure
NVCR
$1.38B
| $14.5M | 0.46% |
172,500
| – | – |
|
75
Centene
CNC
$14.5B
| $14.4M | 0.46% |
229,800
| – | – |
|